免疫检查点抑制剂诱导的甲状腺炎在PET/CT上显示高[68Ga]Ga-FAPI-46和[18F]FDG摄取:一例报告
一例69岁肉瘤样胸膜间皮瘤男性患者,接受纳武利尤单抗3周期联合伊匹木单抗2周期后出现结肠炎(免疫相关不良事件,irAE),停用治疗并开始大剂量泼尼松龙。1至2周后行FDG和FAPI PET/CT,两者均显示甲状腺弥漫性显著摄取。扫描前生化提示甲状腺功能减退,随后数周进一步恶化,诊断为irAE甲状腺炎。
要点
- irAE甲状腺炎可表现为甲状腺弥漫性FDG和FAPI高摄取。
- 接受免疫检查点抑制剂治疗的患者出现甲状腺弥漫性摄取需警惕irAE甲状腺炎。
- FAPI在irAE甲状腺炎中的摄取此前仅报道过一次。
核心结论
- 免疫检查点抑制剂诱导的甲状腺炎在FDG和FAPI PET/CT上均表现为甲状腺弥漫性显著摄取。
研究设计与样本
- 个案报告:一例69岁男性肉瘤样胸膜间皮瘤患者,接受纳武利尤单抗3周期联合伊匹木单抗2周期治疗后出现irAE结肠炎。
主要发现
- 停用免疫治疗并开始大剂量泼尼松龙后1至2周,FDG和FAPI PET/CT均显示甲状腺弥漫性显著摄取。
- 扫描前生化提示甲状腺功能减退,随后数周进一步恶化,诊断为irAE甲状腺炎。
临床怎么用
- 免疫检查点抑制剂治疗患者行PET/CT发现甲状腺弥漫性FDG或FAPI高摄取时,应结合甲状腺功能检查考虑irAE甲状腺炎。
局限性
- 单个病例报告,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 69-year-old man diagnosed with sarcomatoid pleural mesothelioma received 3 cycles of nivolumab with 2 cycles of ipilimumab. Treatment was terminated after the patient developed colitis-an immune-related adverse event (irAE). High-dose prednisolone was initiated. Between 1 and 2 weeks later, the patient underwent FDG- and FAPI PET/CT, both exhibiting prominent, diffuse uptake in the thyroid gland. Biochemistry just before the scans revealed hypothyroidism with further derangement in the following weeks. The patient was diagnosed with irAE thyroiditis. FAPI uptake in chronic thyroiditis has been previously described, whereas uptake in irAE thyroiditis has only been reported once.
引用
- Thostrup AH, Bentestuen M, Rasmussen TL, et al. Thyroiditis Induced by Immune Checkpoint Inhibitors Exhibits High [ 68 Ga]Ga-FAPI-46 and [ 18 F]FDG Uptake on PET/CT : A Case Report. Clin Nucl Med. 2026. PMID: 41949416. doi:10.1097/RLU.0000000000006444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。